- Home
- OMH vs NCEL Comparison
OMH vs NCEL Comparison
Compare OMH & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMH | NCEL |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | Singapore | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 20.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | OMH | NCEL |
|---|---|---|
| Price | $0.80 | $2.09 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.9K | ★ 90.8K |
| Earning Date | 04-17-2026 | 12-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,264,748.00 | N/A |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 78.86 | N/A |
| 52 Week Low | $0.59 | $2.12 |
| 52 Week High | $5.10 | $7.64 |
Technical Indicators
Market Signals| Indicator | OMH | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | N/A |
| Support Level | $0.80 | N/A |
| Resistance Level | $0.84 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 18.60 | 0.00 |
Price Performance
Historical ComparisonAbout OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.